We've issued research covering Diaceutics's results for the half-year to 30th June 2022. This period has strongly validated the transition to a platform model, which now represents c.76% of revenue, a level reached about a year ahead of expectations. Not only has revenue grown 25%, but its quality as significantly improved too: 37% of revenue is now derived from multi-year subscription contracts that auto-renew, with an annual break clause. Early indicators lead us to expect low churn and high ....
27 Sep 2022
Diaceutics - 1H22 Results - Sep 2022
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Diaceutics - 1H22 Results - Sep 2022
Diaceutics Plc (DXRX:LON) | 104 -0.5 (-0.5%) | Mkt Cap: 87.7m
- Published:
27 Sep 2022 -
Author:
Oliver Juggins -
Pages:
8
We've issued research covering Diaceutics's results for the half-year to 30th June 2022. This period has strongly validated the transition to a platform model, which now represents c.76% of revenue, a level reached about a year ahead of expectations. Not only has revenue grown 25%, but its quality as significantly improved too: 37% of revenue is now derived from multi-year subscription contracts that auto-renew, with an annual break clause. Early indicators lead us to expect low churn and high ....